# Brodalumab

## Lumicef 210mg/1.5mL inj

##### 臨採

| TAH Drug Code      | [ILUMI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILUMI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Plaque Psoriasis** Indicated for the treatment of adults with moderate to severe plaque psoriasis who are appropriate candidates for systemic therapy. 2. **Pustular Psoriasis** Indicated for the treatment of adults with pustular psoriasis who are appropriate candidates for systemic therapy. 3. **Psoriatic Arthritis** Indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or are intolerant to disease-modifying antirheumatic drugs (DMARDs). 4. **Ankylosing Spondylitis** Indicated for the treatment of adult patients with active ankylosing spondylitis. |
| Dosing             | SC, 210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Crohn disease. Clinically significant hypersensitivity to brodalumab or to any of the components of the product or component of the container.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Common: Diarrhea (2.2%), Infectious disease (25.4%), Mycosis (1.8-2.4%), Arthralgia (4.7%), Headache (4.3%), Pain in throat (2.1%), Fatigue (2.6%) Serious: Neutropenia, Grade 3 or greater (0.5%), Cryptococcal meningitis, Suicidal thoughts, Suicide                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/brodalumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

